Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials.
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Biomarkers, Tumor
Child
Child, Preschool
DNA Copy Number Variations
DNA Methylation
Diagnosis, Differential
Disease Management
Disease Susceptibility
Female
Germ-Line Mutation
Humans
Infant
Male
Mutation
Prognosis
Rhabdoid Tumor
/ diagnosis
SMARCB1 Protein
/ genetics
Teratoma
/ diagnosis
Treatment Outcome
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 05 2021
15 05 2021
Historique:
received:
05
12
2020
revised:
08
02
2021
accepted:
11
03
2021
pubmed:
20
3
2021
medline:
17
3
2022
entrez:
19
3
2021
Statut:
ppublish
Résumé
Report relevance of molecular groups to clinicopathologic features, germline Seventy-four participants with newly diagnosed ATRT were treated in two trials: infants (SJYC07: age < 3 years; Twenty-four participants (32%) were alive at time of analysis at a median follow-up of 8.4 years (range, 3.1-14.1 years). Methylation profiling classified 64 ATRTs as TYR ( Among infants, those with ATRT-TYR had the best OS. ATRT-SHH was associated with metastases and consequently with inferior outcomes. Children with nonmetastatic ATRT benefit from postoperative CSI and adjuvant chemotherapy.
Identifiants
pubmed: 33737307
pii: 1078-0432.CCR-20-4731
doi: 10.1158/1078-0432.CCR-20-4731
pmc: PMC8127412
mid: NIHMS1685503
doi:
Substances chimiques
Biomarkers, Tumor
0
SMARCB1 Protein
0
SMARCB1 protein, human
0
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2879-2889Subventions
Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Cancer. 2012 Aug 1;118(15):3812-21
pubmed: 22180295
J Clin Invest. 2012 Aug;122(8):2983-8
pubmed: 22797305
Lancet Oncol. 2015 May;16(5):569-82
pubmed: 25882982
Neuro Oncol. 2020 Dec 07;:
pubmed: 33283872
Pediatr Blood Cancer. 2014 May;61(5):919-21
pubmed: 24123847
Neuro Oncol. 2019 Oct 9;21(10):1319-1330
pubmed: 30976811
Am J Surg Pathol. 2011 Jun;35(6):933-5
pubmed: 21566516
Lancet Oncol. 2006 Oct;7(10):813-20
pubmed: 17012043
J Clin Oncol. 2018 Sep 20;36(27):2762-2769
pubmed: 30091946
J Clin Oncol. 2020 Oct 1;38(28):3352
pubmed: 32730182
Pediatr Blood Cancer. 2014 Jan;61(1):95-101
pubmed: 23934933
Pediatr Blood Cancer. 2011 Jul 1;56(7):1026-31
pubmed: 20848638
J Clin Oncol. 2020 Oct 1;38(28):3353-3354
pubmed: 32730180
Eur J Cancer. 2012 Feb;48(3):353-9
pubmed: 22023887
J Clin Oncol. 2004 Jul 15;22(14):2877-84
pubmed: 15254056
Pediatr Dev Pathol. 2015 Jan-Feb;18(1):49-58
pubmed: 25494491
Pediatr Blood Cancer. 2011 Dec 1;57(6):978-85
pubmed: 21796761
Neuro Oncol. 2020 Jul 7;22(7):1006-1017
pubmed: 31883020
J Clin Oncol. 2005 Mar 1;23(7):1491-9
pubmed: 15735125
Cancer Res. 1999 Jan 1;59(1):74-9
pubmed: 9892189
J Clin Oncol. 2009 Jan 20;27(3):385-9
pubmed: 19064966
Cancer. 2012 Sep 1;118(17):4212-9
pubmed: 22213196
J Clin Oncol. 2020 Apr 10;38(11):1175-1185
pubmed: 32105509
Cancer. 2017 Feb 15;123(4):682-687
pubmed: 27861763
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
Nature. 1998 Jul 9;394(6689):203-6
pubmed: 9671307
Cancer Med. 2016 Aug;5(8):1765-75
pubmed: 27228363
J Neurooncol. 2016 Jan;126(1):81-90
pubmed: 26608522
Cancer Cell. 2016 Mar 14;29(3):379-393
pubmed: 26923874